CRMD - CorMedix EPS misses by $0.04 beats on revenue
CorMedix (NASDAQ:CRMD): Q3 GAAP EPS of -$0.22 misses by $0.04. Revenue of $0.04M (-55.6% Y/Y) beats by $0.04M. Press Release Total cash on hand and short-term investments as of September 30, 2021 was $72.0M, excluding restricted cash of $0.2M. The Company believes that, based on the Company’s cash resources at September 30, 2021, it has sufficient resources to fund operations at least through 2022, after taking into consideration the costs for re-submission of the NDA and initial preparations for the commercial launch for DefenCath.
For further details see:
CorMedix EPS misses by $0.04, beats on revenue